SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
PCI Biotech Commences Phase I/II Trials of Amphinex(R) Light-Mediated Therapy Aims to Overcome Both Tumour Cell Uptake Barriers and Toxicity Problems